Cabita 500mg 7pcs Tablet

✔️ Generic Name:

Capecitabine

✔️ Pharmacology:

• Capecitabine is an orally administered prodrug that is converted into fluorouracil (5-FU) in the tumor, where it inhibits DNA synthesis, impeding tumor growth.
• The conversion of Capecitabine to 5-FU is catalyzed by thymidine phosphorylase, an enzyme more concentrated in tumors than normal tissues.
• The active metabolites, FdUMP and FUTP, cause cell damage by interfering with DNA and RNA synthesis, leading to cell death.

✔️ Dosage and Administration:

• Monotherapy: 1250 mg/m² orally twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles.
• Adjuvant Treatment: Typically recommended for 6 months (8 cycles).
• In Combination with Docetaxel: 1250 mg/m² twice daily for 2 weeks followed by a 7-day rest period, combined with docetaxel at 75 mg/m² every 3 weeks. The dose may need adjustment in patients with renal impairment.

A patient with a body surface area of 1.7 m² should take 4 tablets of 500 mg and 1 tablet of 150 mg twice daily, as prescribed by a doctor. Tablets should be taken within 30 minutes of meals, swallowed whole, and not crushed.

✔️ Overdose Effects:

Overdose symptoms may include nausea, vomiting, diarrhea, mucositis, gastrointestinal bleeding, and bone marrow depression. Supportive treatment should be initiated to manage these symptoms.

✔️ Side Effects: Cabita 500

• Common side effects include abdominal pain, rash, dry or itchy skin, tiredness, loss of appetite, diarrhea, vomiting, nausea, stomatitis, hand-and-foot syndrome, fever, infection, chest pain, and Steven-Johnson syndrome.

✔️ Drug Interactions: Cabita 500

• Anticoagulants: Monitor INR/prothrombin time regularly to adjust the anticoagulant dose.
• Phenytoin: Phenytoin levels should be monitored; dose adjustment may be required.
• Leucovorin: This may enhance the toxicity of fluorouracil.
• CYP2C9 Substrates: Caution when used with these drugs.
• Food: Food may reduce the absorption rate and extent of Capecitabine.

✔️ Contraindications: Cabita 500

• Severe renal impairment
• Hypersensitivity to Capecitabine or any component of the drug
• Leukopenia, neutropenia, or thrombocytopenia
• Severe reactions to fluoropyrimidine therapy
• Complete DPD deficiency
• Pregnancy and breastfeeding

✔️ Pregnancy and Lactation:

• Pregnancy Category D: Capecitabine may cause fetal harm. Women are advised to discuss potential risks with their doctor.
• Breastfeeding: Capecitabine is excreted in human breast milk, so breastfeeding should be discontinued during treatment and for 2 weeks after the final dose.

✔️ Precautions and Warnings:

• Coagulopathy: Monitor anticoagulant response (INR) and adjust the dose as necessary.
• Diarrhea: Discontinue treatment until diarrhea resolves or becomes manageable. Antidiarrheal treatment may be needed.
• Cardiotoxicity: Patients with a history of coronary artery disease should use Capecitabine with caution.
• Severe Toxicity: In patients with low or absent DPD activity, the drug may cause severe reactions; treatment should be withheld or discontinued in such cases.
• Dehydration and Renal Failure: Dehydration can lead to renal failure; stop treatment until hydration is corrected.
• Mucocutaneous Reactions: Severe reactions, including Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported. Permanent discontinuation is recommended if severe reactions occur.
• Hyperbilirubinemia: Treatment should be interrupted until bilirubin levels normalize.

✔️ Storage:

Store in a dry place below 30°C. Keep away from light and out of reach of children.